libertas primordium on Nostr: # Comparing mitragynine to opioids Mitragynine has opioid activity—it is not ...

# Comparing mitragynine to opioids

Mitragynine has opioid activity—it is not pharmacologically separate from opioids. It is the main alkaloid in kratom and acts on the same μ-opioid receptor (“mu receptor”) targeted by morphine and other opioid painkillers. The useful comparison is therefore between mitragynine’s atypical opioid pharmacology and that of conventional opioid drugs, rather than “kratom compound versus opioid.”

The main functional differences concern how strongly it activates that receptor, what your body converts it into, and which other biological systems it affects.

1. It activates opioid receptors differently

Drugs such as morphine produce substantial μ-receptor activation, which contributes to both pain relief and potentially dangerous suppression of breathing. Mitragynine has comparatively low intrinsic efficacy at the human μ receptor: in laboratory studies, it behaves as a partial agonist, activating the receptor less strongly than a full agonist can in the same experimental system.

Think of receptor binding and receptor activation as two separate properties. A drug can attach to a receptor without turning its activity up very much. Consequently, “partial agonist” does not simply mean “a smaller dose of a strong opioid.” It describes a different ability to activate the receptor. The resulting effects still depend on the tissue, dose, and other compounds present.

This distinction is not unique to mitragynine. Buprenorphine is also a partial μ-opioid agonist, so not all conventional opioid medications belong on the “full agonist” side of the comparison. Sharing partial agonism does not make mitragynine and buprenorphine interchangeable.

2. Its metabolite is an important part of the story

Mitragynine can be converted into 7-hydroxymitragynine, commonly abbreviated 7-OH, through metabolism involving the enzyme CYP3A4. That metabolite has substantially greater opioid-receptor potency than mitragynine itself. Researchers demonstrated this conversion in human liver preparations and found that the metabolite accounted for much of mitragynine’s opioid-mediated pain relief in mice. The exact contribution to effects in humans is less firmly established.

This means that what mitragynine does in an isolated receptor experiment is not necessarily what happens after someone swallows it. The parent compound and the metabolites formed afterward can have different effects.

It also means that ordinary kratom leaf, purified mitragynine, and products enriched with 7-OH should not be treated as equivalent. Natural leaf contains relatively little 7-OH; concentrated products can expose someone directly to much larger amounts of this more potent compound.

3. Its effects are not exclusively opioid effects

Mitragynine’s pharmacology extends beyond μ-opioid receptors. For example, laboratory and animal studies have investigated interactions with alpha-2 adrenergic receptors, part of the system that responds to norepinephrine. However, receptor binding does not automatically establish a meaningful effect in humans, and the experimental findings are not simple enough to describe mitragynine as merely “an opioid plus a stimulant.”

There is another distinction here: kratom is a mixture, whereas mitragynine is one molecule. Kratom contains numerous other alkaloids, so an effect reported after taking kratom cannot automatically be attributed to mitragynine alone.

4. Breathing suppression may differ—but “it cannot suppress breathing” is wrong

There is experimental evidence that mitragynine’s respiratory effects differ considerably from those of morphine. In a 2025 rat study, intravenously administered mitragynine increased breathing frequency rather than suppressing it, whereas 7-OH and morphine both caused significant respiratory depression. Naloxone reversed the breathing suppression caused by 7-OH and morphine. High-dose mitragynine nevertheless caused seizure-like toxicity in some animals. These findings do not establish a safe dose or a guaranteed respiratory ceiling for oral use in humans.

You may encounter an explanation that mitragynine favors G-protein signaling over β-arrestin recruitment, two processes associated with opioid-receptor activation. Laboratory studies support this distinctive signaling profile. But the popular conclusion—“it avoids β-arrestin, therefore it cannot cause an opioid overdose”—goes beyond the evidence.

Broader opioid research suggests that low receptor-activating efficacy, not necessarily signaling bias alone, may explain some improved safety profiles. The relative contributions remain debated; neither characteristic is a guarantee against respiratory depression.

5. Dependence and other opioid-type effects remain possible

Kratom products can produce nausea, constipation, sedation, tolerance, physical dependence, and withdrawal. Their atypical pharmacology does not eliminate these possibilities. Human evidence also does not establish a reliable, universal conversion between a quantity of mitragynine and an equivalent dose of a prescription opioid. Kratom and its alkaloids are not FDA-approved treatments for pain or opioid withdrawal.

Bottom line: Mitragynine is best understood as an atypical opioid-active compound with relatively low μ-receptor efficacy, additional non-opioid actions, and a more potent opioid metabolite. Those differences can meaningfully change its effects compared with morphine—but they do not make it opioid-free, non-dependence-forming, or incapable of serious toxicity. Mitragynine and concentrated 7-OH are especially important not to conflate.